Conclusions.
In conclusion, our case illustrates a favorable outcome at one year post transseptal TMViV for mitral bioprosthesis failure in a patient at high-risk for surgical reintervention. Transseptal TMViV should be considered as an alternative to conventional surgery especially when the anatomy is favorable for the implantation of a large THV.
Disclosure : S Noble received institutional grants from Edwards Life Sciences.
Funding sources : none